Multiple myeloma (MM) cells have been shown to have increased nuclear export protein expression that has been associated with increased lytic lesions as well as shorter progression-free survival and overall survival.

Selinexor, an inhibitor of nuclear export, has shown benefit in treatment-refractory MM when used alone or in combination with dexamethasone or other conventional MM therapies.

Results from numerous clinical trials evaluating selinexor in MM are eagerly anticipated to help define the role of nuclear export inhibition in MM.